Milbrandt Lab publishes paper in eLife

The Milbrandt and DiAntonio Labs have a new paper in eLife, “SARM1 depletion rescues NMNAT1 dependent photoreceptor cell death and retinal degeneration.” Yo Sasaki, PhD, Associate Professor in the Department of Genetics at Washington University School of...

Biotech from Jeff Milbrandt and team acquired by Eli Lilly

Eli Lilly & Company recently acquired Disarm Therapeutics, a pre-clinical NAD-boosting company treating neuropathy and neurodegenerative diseases, for $135 million and a potential additional $1.2 billion in milestones. Disarm was founded by Atlas Venture; Jeff...

Milbrandt Lab publishes paper in Molecular Neurobiology

The Milbrandt Lab had a paper published recently in Molecular Neurobiology. The paper, “DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon Degeneration,” was published in...

Jeff Milbrandt senior author on new SARM1 paper in JCI Insight

Jeffrey Milbrandt, M.D., Ph.D., the James S. McDonnell Professor of Genetics and head of the Department of Genetics at Washington University School of Medicine, is a senior author on a new paper from the DiAntonio Lab recently published in JCI Insight. The paper,...